ARTICLE | Clinical News

Repligen falls on RG1068 data

December 10, 2009 1:31 AM UTC

Repligen Corp. (NASDAQ:RGEN) fell $0.76 (16%) to $3.91 on Wednesday after reporting that RG1068 in combination with MRI missed the predetermined criteria for success of meeting the co-primary endpoints with two out of three blinded radiologists in a Phase III trial to improve functional MRI of the pancreas. The co-primary endpoints were improved sensitivity of detecting pancreatic ducts' structural abnormalities compared to MRI alone with minimal loss in specificity (<7.5%). Only one of three radiologists achieved both measures, with two needing to do so for the trial to meet the criteria for success. ...